| Autor: |
Ringheim GE; Inflammation and Immunology Translational Development, Celgene Corporation , Summit, NJ , USA., Lee L, Laws-Ricker L, Delohery T, Liu L, Zhang D, Colletti N, Soos TJ, Schroeder K, Fanelli B, Tian N, Arendt CW, Iglesias-Bregna D, Petty M, Ji Z, Qian G, Gaur R, Weinstock D, Cavallo J, Telsinskas J, McMonagle-Strucko K |
| Jazyk: |
angličtina |
| Zdroj: |
Frontiers in neurology [Front Neurol] 2013 Oct 30; Vol. 4, pp. 169. Date of Electronic Publication: 2013 Oct 30 (Print Publication: 2013). |
| DOI: |
10.3389/fneur.2013.00169 |
| Abstrakt: |
Teriflunomide is an oral disease-modifying therapy recently approved in several locations for relapsing-remitting multiple sclerosis. To gain insight into the effects of teriflunomide, immunocyte population changes were measured during progression of experimental autoimmune encephalomyelitis in Dark Agouti rats. Treatment with teriflunomide attenuated levels of spinal cord-infiltrating T cells, natural killer cells, macrophages, and neutrophils. Teriflunomide also mitigated the disease-induced changes in immune cell populations in the blood and spleen suggesting an inhibitory effect on pathogenic immune responses. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
